Loading
Trials stop following patients after a few years, so late side effects and late relapses are missed. Link trial participants to national records so follow-up continues automatically for decades.
Late effects of cancer treatment (second cancers, cardiac disease, endocrine failure) appear decades later, long after trials close. The Childhood Cancer Survivor Study shows the value of long follow-up but relies on costly active contact. The proposal requires consent for registry linkage in every publicly funded trial and funds automated linkage of trial participants to cancer, death and hospital records for 30 years, with pooled analysis across trials.
Shares Assessment of the Clinical Benefit of Cancer Drugs Receiving Accelerated Approval, Weak real-world evidence and registries, Trial design, endpoints and cost.
Shares Assessment of the Clinical Benefit of Cancer Drugs Receiving Accelerated Approval, Weak real-world evidence and registries, Trial design, endpoints and cost.
Shares Assessment of the Clinical Benefit of Cancer Drugs Receiving Accelerated Approval, Children's Oncology Group (COG), Weak real-world evidence and registries.
Shares Assessment of the Clinical Benefit of Cancer Drugs Receiving Accelerated Approval, Weak real-world evidence and registries.
Shares Assessment of the Clinical Benefit of Cancer Drugs Receiving Accelerated Approval, Weak real-world evidence and registries.
Shares Assessment of the Clinical Benefit of Cancer Drugs Receiving Accelerated Approval, Weak real-world evidence and registries.
Shares Assessment of the Clinical Benefit of Cancer Drugs Receiving Accelerated Approval, Weak real-world evidence and registries.
Shares Assessment of the Clinical Benefit of Cancer Drugs Receiving Accelerated Approval, Weak real-world evidence and registries.